Skip to main content
. 2024 Nov 29;10(48):eadp7561. doi: 10.1126/sciadv.adp7561

Fig. 5. Therapeutic effect of PFCE-C25 NEs on the LLC metastatic model.

Fig. 5.

(A) Schematic diagram of the dosing and imaging regimens for each experimental group. i.t., intratracheally; i.p., intraperitoneally. (B) MRI results for immunotherapy monitoring. Red arrow points to the tumor. (C) Lung-solid tumor images in each research group. (D) Weight statistics of the lung-solid tumors in each group (n = 5). The data are presented as the mean ± SD. (E) Representative H&E staining results of the lung in each treatment group. Red arrow points to the tumor. Scale bar, 20 μm. (F) Log-rank survival curve analysis.